Loading organizations...
MedRhythms develops neurotherapeutics to improve walking, mobility, and functional outcomes for individuals with neurological conditions. Its patented platform integrates wearable sensors, software, and music, delivering personalized rhythmic stimulation. This approach leverages neuroscience and clinical algorithms, targeting neural circuitry to facilitate auditory-motor entrainment and enhance movement.
Co-founded in 2015 by Chief Scientific Officer Brian Harris and Owen McCarthy, MedRhythms originated from recognizing Rhythmic Auditory Stimulation (RAS) efficacy in neurorehabilitation. Their insight focused on digitizing and personalizing this evidence-based practice, building a framework from clinical understanding and academic research.
MedRhythms’ products serve patients with mobility impairments from neurological injuries and diseases like stroke, multiple sclerosis, and Parkinson’s. The company's mission is to positively impact these individuals globally by redefining brain health through its music and technology-driven neurotherapeutics. It envisions a future where all patients with neurological conditions access high-quality care.
Medrhythms has raised $25.0M across 1 funding round.
Medrhythms has raised $25.0M in total across 1 funding round.
Medrhythms has raised $25.0M in total across 1 funding round.
Medrhythms's investors include Christopher Harris, Stephen Bruso, Founder Collective, NFX, Werth Family Investment Associates.
MedRhythms is a digital therapeutics company developing prescription neurotherapeutics that combine wearable sensors, software, music, and neuroscience to improve walking and mobility in patients with neurologic conditions like chronic stroke, Parkinson's disease, and multiple sclerosis.[1][2][3] Its platform uses Rhythmic Auditory Stimulation (RAS), an evidence-based intervention, to deliver personalized, real-time auditory-motor entrainment therapy, addressing gait impairments where clinician shortages limit access.[1][7] The company serves patients via prescription products, clinicians, and rehabilitation settings, solving scalability issues in neurologic rehab by enabling at-home or clinical use with over 30,000 hours of prior patient care informing its design; it has shown growth through FDA Breakthrough Device Designation in 2020, multiple patents, clinical trials, and investments including from Bose.[3][4]
MedRhythms originated as a Neurologic Music Therapy practice founded by Brian Harris, a board-certified Neurologic Music Therapist, at Spaulding Rehabilitation Hospital (ranked among the top U.S. rehab hospitals) around 2013-2015.[1][3][4][7] Harris, one of only 350 globally trained in neuroscience-music applications, grew it into the U.S.'s most comprehensive such practice, delivering over 30,000 hours of care.[1] In 2017, spotting scalability limits amid rising demand for gait disorder treatments, Harris co-founded the company with Owen McCarthy to tech-enable RAS via sensors and software.[1][7] Pivotal early moments included relocating to Portland, Maine, for talent and innovation support; securing FDA Breakthrough Designation for its chronic stroke product in 2020; and partnerships like Universal Music Group for curated music.[1][3][4]
MedRhythms rides the digital therapeutics and neurotech wave, merging AI-driven personalization, wearables, and non-pharmacologic interventions amid rising neurologic disease prevalence (e.g., 2.5M+ annual U.S. strokes/TBIs).[4][8] Timing aligns with FDA's support for Breakthrough Devices, clinician shortages, and post-pandemic demand for at-home rehab, amplified by neuroplasticity research validating music's brain-wide effects.[1][3] Market tailwinds include aging populations, MS/PD growth, and investor interest in audio-health crossovers (e.g., Bose); it influences the ecosystem by pioneering RAS scalability, partnering with hospitals like Spaulding/Cleveland Clinic, and expanding music's role in precision medicine beyond pharma.[1][4][6]
MedRhythms is poised to launch its chronic stroke therapeutic post-pivotal trial completion, with pipeline expansion into Parkinson's, MS, and beyond via ongoing multi-site studies and neuroimaging.[3][6] Trends like AI gait analysis, immersive audio therapeutics, and value-based care will accelerate adoption, potentially evolving it into a multi-condition platform leader. As neurotech matures, its clinician-tech hybrid could redefine accessible rehab, scaling Harris's therapy legacy to millions while attracting pharma partnerships. This positions MedRhythms as a pioneer harmonizing music, data, and neuroscience for brain health transformation.[1][2][8]
Medrhythms has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series B in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2021 | $25.0M Series B | Christopher Harris, Stephen Bruso | Founder Collective, NFX, Werth Family Investment Associates |